KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Merck (MRK) EPS (Weighted Average and Diluted) (2016 - 2026)

Merck has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at -$1.72 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 185.57% to -$1.72 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.56 through Mar 2026, down 48.18% year-over-year, with the annual reading at $7.28 for FY2025, 8.01% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$1.72 for Q1 2026 at Merck, down from $1.2 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $2.32 in Q3 2025 and troughed at -$2.35 in Q2 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is $1.48 (2024), against an average of $1.07.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 251.61% in 2023 and then soared 408.33% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.18 in 2022, then tumbled by 140.68% to -$0.48 in 2023, then soared by 408.33% to $1.48 in 2024, then decreased by 18.92% to $1.2 in 2025, then crashed by 243.33% to -$1.72 in 2026.
  • Per Business Quant, the three most recent readings for MRK's EPS (Weighted Average and Diluted) are -$1.72 (Q1 2026), $1.2 (Q4 2025), and $2.32 (Q3 2025).